Moderna Stock Slides After Posting Data From Early Flu Vaccine Study


Moderna  (MRNA) – Get Moderna, Inc. Report shares moved lower Friday after the drugmaker posted promising early stage data from its developing seasonal flu vaccine as investors await an update on the efficacy of its Covid vaccine against the newly-identified Omicron variant. 

Moderna said the study showed that its ‘mRNA-1010’ vaccine produced a boost in titers against all four flu strains, even with lower dosages, with no significant side-effects. A phase 2 study is now fully-enrolled, Moderna said, with plans for a phase 3 study also underway. 





Read More: Moderna Stock Slides After Posting Data From Early Flu Vaccine Study

You might also like